Provided by Healio
October 19, 2013
BRUSSELS — Christoph Boesecke, MD, an infectious disease specialist at Bonn University Hospital in Germany, reviews his poster presentation here at EACS 2013 on factors associated with treatment response in patients with HIV/HCV coinfection. Study results indicate that rapid virological response 4 weeks after the initiation of dual treatment (pegylated interferon and ribavirin) and genotypes 2 and 3 predicted SVR in patients.
Disclosure: Boesecke reports no relevant financial disclosures.
No comments:
Post a Comment